Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.
Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, Gee A, Cottler-Fox M, Rooney C, Barlogie B, van Rhee F. Szmania S, et al. J Immunother. 2015 Jan;38(1):24-36. doi: 10.1097/CJI.0000000000000059. J Immunother. 2015. PMID: 25415285 Free PMC article. Clinical Trial.
Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.
Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, Moreno A, Dupont B, Hsu KC, Baxter-Lowe LA, Cottler-Fox M, Shaughnessy JD Jr, Barlogie B, van Rhee F. Shi J, et al. Br J Haematol. 2008 Dec;143(5):641-53. doi: 10.1111/j.1365-2141.2008.07340.x. Epub 2008 Oct 16. Br J Haematol. 2008. PMID: 18950462 Free PMC article.
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Usmani SZ, Sawyer J, Rosenthal A, Cottler-Fox M, Epstein J, Yaccoby S, Sexton R, Hoering A, Singh Z, Heuck CJ, Waheed S, Chauhan N, Johann D, Abdallah AO, Muzaffar J, Petty N, Bailey C, Crowley J, van Rhee F, Barlogie B. Usmani SZ, et al. Blood. 2013 Jun 6;121(23):4753-7. doi: 10.1182/blood-2012-11-466961. Epub 2013 Apr 19. Blood. 2013. PMID: 23603914 Free PMC article.
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G, Bolejack V, Zangari M, Epstein J, Petty N, Steward D, Jenkins B, Gurley J, Sullivan E, Crowley J, Shaughnessy JD Jr. Barlogie B, et al. Br J Haematol. 2007 Jul;138(2):176-85. doi: 10.1111/j.1365-2141.2007.06639.x. Br J Haematol. 2007. PMID: 17593024 Free article. Clinical Trial.
Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.
Yi Q, Szmania S, Freeman J, Qian J, Rosen NA, Viswamitra S, Cottler-Fox M, Barlogie B, Tricot G, van Rhee F. Yi Q, et al. Br J Haematol. 2010 Sep;150(5):554-64. doi: 10.1111/j.1365-2141.2010.08286.x. Epub 2010 Jul 7. Br J Haematol. 2010. PMID: 20618329 Free PMC article. Clinical Trial.
139 results